Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of LY-CovMab in Chinese Healthy Subjects
NCT04973735Phase 1Unknown
- Sponsor
- Luye Pharma Group
- Start
- Nov 2020
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY-CovMab in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by Luye Pharma Group. Primary endpoints: Treatment-emergent Changes in Body Temperature up to 99 days, Treatment-emergent Changes in Respiratory Rate up to 99 days and 6 more. Status: unknown.
02
Drugs
LY-CovMab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04973735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04973735.